AUTHORS
Young Jun Shim, PhD, John Barnard, PhD2, Claudia Diaz-Montero, PhD3, Alok Khorana, MD4, Keith McCrae, MD5
AFFILIATIONS
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
ABSTRACT
Background: Immune checkpoint inhibitors (ICI) are associated with an increased risk of early thrombotic events in cancer patients, frequently occurring within the first 2-4 treatment cycles. While tumor-derived tissue factor contributes to cancer-associated thrombosis, the rapid onset of ICI-associated venous thromboembolism suggests additional acute immune-mediated mechanisms. We hypothesized that ICI-induced T cell activation promotes neutrophil extracellular trap (NET) formation, driving immunothrombosis.
Objectives: To determine whether ICI induces T cell-dependent NET formation that contributes to thrombosis and to evaluate its clinical relevance through longitudinal analysis of paired patient plasma samples.
Methods: CT26 murine colorectal tumor-bearing BALB/c mice received dual ICI (anti-PD-1/anti-CTLA-4) prior to inferior vena cava (IVC) ligation. Thrombus composition was assessed by immunostaining for Ly6G and citrullinated histone H3 (CitH3), and circulating NET formation was quantified by plasma CitH3-containing nucleosome (H3R8Cit nucleosome). T cell dependency was evaluated by CD4+/CD8+ T cell depletion, and neutrophil contribution was assessed using anti-Ly6G antibody-mediated depletion. Systemic inflammatory responses were evaluated by plasma cytokine profiling. Longitudinal paired plasma samples collected before and approximately 21 days after ICI initiation were analyzed from 29 cancer patients (17 without VTE, 12 with VTE). Exploratory analyses compared patients with early-onset VTE (within 2 months; days 27, 28, and 34; n=3) with matched VTE-free controls (n=3) and patients with late-onset VTE (5–11 months; diagnosed at days 155, 224, and 310; n=3).
Results: ICI-treated mice developed significantly larger IVC thrombi enriched in Ly6G+ neutrophils (44.5% vs 19.6%) and CitH3+ NETs (27.5% vs 13.2%). Anti-Ly6G-mediated neutrophil depletion significantly reduced thrombus size in ICI-treated mice (p=0.0444), reaching levels comparable to IgG-treated controls, supporting neutrophils as critical effectors of ICI-associated immunothrombosis. ICI markedly increased circulating H3R8Cit nucleosomes, which were reduced by >90% following CD4+/CD8+ T cell depletion, demonstrating that ICI-induced NET formation is T cell-dependent. T cell depletion also attenuated ICI-induced systemic inflammatory responses, including increases in IFN-γ, TNF-α, IL-16, CXCL2 and SDF-1α. In exploratory clinical analyses, patients with early-onset VTE (within 2 months after ICI initiation; diagnosed at days 27, 28, and 34) showed early NET-associated changes compared with VTE-free and late-onset VTE patients. Plasma H3R8Cit nucleosome levels showed a consistent upward trend at day 21 post-ICI compared with pretreatment baselines, preceding clinical VTE by 6–13 days. This increase was not observed in matched VTE-free controls or late-onset VTE (5–11 months after ICI initiation; diagnosed at days 155, 224, and 310).
Conclusions: ICI promotes a T cell-dependent inflammatory program characterized by cytokine responses and NET formation, contributing to thrombus development during cancer immunotherapy. Early NET-associated changes precede clinical thrombosis and support NETs as candidate biomarkers and potential therapeutic targets for mitigating acute thrombotic risk following ICI.
DISCLOSURES
Young Jun Shim, PhD: No relevant conflicts of interest to declare.